PrEP drug gets TGA approval

HIV groups have welcomed the TGA decision to register the drug Truvada (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP).

The approval of the once-daily pill for use by HIV-negative men at high risk of the infection will be a major advance in preventing the transmission of HIV, according to the Australian Federation of AIDS Organisations (AFAO).

"In registering Truvada, the TGA has confirmed that this is a safe and effective way of preventing HIV transmission through sex,” said